ZFP69
Zinc finger protein 69 homolog
Also known as: FLJ16030, ZFP69_HUMAN, ZFP69A, ZKSCAN23A, ZNF642, ZSCAN54A
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q49AA0
- Gene
- ZFP69
- Ensembl
- ENSG00000187815
- Chromosome
- 1
- Canonical length
- 526 aa
- Protein class
- Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of lipid metabolic process and regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
526 residues, UniProt reviewed canonical sequence.
>Q49AA0|ZFP69
1 MPQQLLITLP TEASTWVKLQ HPKKAVEGAP LWEDVTKMFE GEALLSQDAE DVKTQRESLE
61 DEVTPGLPTA ESQELLTFKD ISIDFTQEEW GQLAPAHQNL YREVMLENYS NLVSVGYQLS
121 KPSVISQLEK GEEPWMAEKE GPGDPSSDLK SKIETIESTA KSTISQERLY HGIMMESFMR
181 DDIIYSTLRK VSTYDDVLER HQETCMRDVR QAILTHKKRV QETNKFGENI IVHSNVIIEQ
241 RHHKYDTPTK RNTYKLDLIN HPTSYIRTKT YECNICEKIF KQPIHLTEHM RIHTGEKPFR
301 CKECGRAFSQ SASLSTHQRI HTGEKPFECE ECGKAFRHRS SLNQHHRTHT GEKPYVCDKC
361 QKAFSQNISL VQHLRTHSGE KPFTCNECGK TFRQIRHLSE HIRIHTGEKP YACTACCKTF
421 SHRAYLTHHQ RIHTGERPYK CKECGKAFRQ RIHLSNHKTV HTGVKAYECN RCGKAYRHDS
481 SFKKHQRHHT GEKPYECNEC GKAFSYNSSL SRHHEIHRRN AFRNKVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ZFP69 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 3.9 nTPM
Expression across tissuesHPA
Tissue
- spinal cord: 3.9 nTPM
- testis: 3.4 nTPM
- basal ganglia: 3.1 nTPM
- amygdala: 3 nTPM
- midbrain: 3 nTPM
- spleen: 3 nTPM
Single-cell type
- cardiomyocytes: 74 nCPM
- late primary spermatocytes: 18 nCPM
- adipocytes: 14 nCPM
- fibro-adipogenic progenitors: 11 nCPM
- oligodendrocyte progenitor cells: 9.7 nCPM
- medullary thymic epithelial cells: 9.6 nCPM
Immune cell
- NK-cell: 1.9 nTPM
- MAIT T-cell: 0.6 nTPM
- memory CD8 T-cell: 0.6 nTPM
- naive CD8 T-cell: 0.6 nTPM
- gdT-cell: 0.5 nTPM
- memory CD4 T-cell: 0.4 nTPM
Brain region
- white matter: 5.7 nTPM
- basal ganglia: 5.5 nTPM
- medulla oblongata: 5.3 nTPM
- midbrain: 5.1 nTPM
- hypothalamus: 5 nTPM
- amygdala: 4.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.11
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.22
- DepMap mean gene effect
- -0.25
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- lipid metabolic process
- regulation of lipid metabolic process
- regulation of transcription by RNA polymerase II
Molecular functions
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ZFP69 as an antibody target. Whether an autoantibody or antibody against ZFP69 could matter depends on whether native ZFP69 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ZFP69 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ZFP69 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...